To evaluate the clinical benefits, safety profiles, and optimal duration of long-term antiplatelet therapy following percutaneous coronary intervention.
Synthesized current clinical evidence and randomized trials assessing single and dual antiplatelet regimens following stent implantation.
Evaluated patient-specific factors influencing the trade-off between recurrent ischemic events and major bleeding complications.
Extended antiplatelet regimens reduce the incidence of late stent thrombosis and recurrent myocardial infarction but significantly increase major bleeding risk.
Tailoring antiplatelet duration based on individualized ischemic and bleeding risk stratification improves overall clinical outcomes compared to standard fixed-duration strategies.